The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 30, 2014
Filed:
Jan. 20, 2012
Feng Xiao, Union City, CA (US);
Xiao-chi Jia, Los Angeles, CA (US);
Meina Liang, Fremont, CA (US);
Orit Foord, Foster City, CA (US);
Scott Klakamp, Fremont, CA (US);
Kam Fai Tse, Clinton, CT (US);
Vincent A. Pollack, Gales Ferry, CT (US);
Luca Rastelli, Guilford, CT (US);
John Herrmann, Bothell, WA (US);
Henri Lichenstein, Guilford, CT (US);
Michael Jeffers, Branford, CT (US);
William Larochelle, Madison, CT (US);
Gulshan Ara, Northford, CT (US);
Peter Mezes, Old Lyme, CT (US);
Andrei Chapoval, Towson, MD (US);
Cyrus Karkaria, Branford, CT (US);
Michael Torgov, Middletown, CT (US);
Juan Davagnino, Madison, CT (US);
Feng Xiao, Union City, CA (US);
Xiao-Chi Jia, Los Angeles, CA (US);
Meina Liang, Fremont, CA (US);
Orit Foord, Foster City, CA (US);
Scott Klakamp, Fremont, CA (US);
Kam Fai Tse, Clinton, CT (US);
Vincent A. Pollack, Gales Ferry, CT (US);
Luca Rastelli, Guilford, CT (US);
John Herrmann, Bothell, WA (US);
Henri Lichenstein, Guilford, CT (US);
Michael Jeffers, Branford, CT (US);
William LaRochelle, Madison, CT (US);
Gulshan Ara, Northford, CT (US);
Peter Mezes, Old Lyme, CT (US);
Andrei Chapoval, Towson, MD (US);
Cyrus Karkaria, Branford, CT (US);
Michael Torgov, Middletown, CT (US);
Juan Davagnino, Madison, CT (US);
Celldex Therapeutics, Inc., Needham, MA (US);
Amgen Fremont, Inc., Fremont, CA (US);
Abstract
The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.